Home / Guidelines / EMA to revise overarching biosimilar guidelines
EMA to revise overarching biosimilar guidelines Posted 09/12/2011

EMA announced on 17 November 2011 that it has published a concept paper asking for comments on topics to be included in a revision of the agency’s 2005 overarching guideline on similar biological medicinal products. The paper will be released for a three-month consultation period.
EMA wants to update its overarching guideline on biosimilar drugs to reflect the growing complexity of biosimilar products and unique issues concerning their development. Since the original overarching biosimilars guideline came into effect in October 2005 several biosimilar products have come onto the EU market, the number of scientific advices given by EMA’s Committee for Human Medicinal Products on the development of biosimilar products has increased significantly, and the regulatory framework is becoming wider, e.g. addition of the guideline for biosimilar monoclonal antibodies [1]. Therefore, due to the development of more complex biosimilars, EMA has proposed a list of several topics for re-evaluation. These include: The concept paper seeks stakeholders’ views on the need to revise the 2005 guideline and is available on the EMA website. The proposed guideline will replace the ‘guideline on similar biological medicinal products (CHMP/437/04)’. Feedback for the concept paper can be submitted until the end of February 2012. EMA expects a draft revised guideline to be released in the first quarter of 2012.
Concept paper on the revision of the guideline on similar biological medicinal product Related article References 1. GaBI Online - Generics and Biosimilars Initiative. EMA adopts guideline on biosimilar monoclonal antibodies [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2011 December 09]. Available from: www.gabionline.net/Guidelines/EMA-adopts-guideline-on-biosimilar-monoclonal-antibodies 2. GaBI Online - Generics and Biosimilars Initiative. EMA plans to revise biosimilar guidelines [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2011 December 09]. Available from: www.gabionline.net/Biosimilars/News/EMA-plans-to-revise-biosimilar-guidelines
Date: 17 November 2011
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/11/WC500117987.pdf
Source: EMA
Comments (0)
Generics News Research General
- The role of authorized generics in Improving a...Generics/Research | Posted 05/03/2021
- Opportunities for generics with Korean patent e...Generics/General | Posted 05/03/2021
- Approving generics of polymer-based parenteral...Generics/Research | Posted 26/02/2021
- AIFA updates the Transparency Lists for genericsGenerics/General | Posted 26/02/2021
Biosimilars News Research General
- Biosimilar patent litigation trends in the USBiosimilars/General | Posted 05/03/2021
- Biosimilars approved in the USBiosimilars/General | Posted 14/08/2015
- Different approaches to the interchangeability...Biosimilars/Research | Posted 05/03/2021
- Efficacy and safety of interferon beta-1a (Reci...Biosimilars/Research | Posted 05/03/2021